Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

The development of treatments beyond traditional chemotherapy has been essential for patients with relapsed or refractory follicular lymphoma, as many eventually progress despite standard regimens and experience cumulative toxicity with repeated chemo-based approaches. Newer therapies aim to deliver deeper, more durable responses while offering improved tolerability and addressing disease that no longer responds to conventional options. In the second-line setting, commonly used regimens include immunotherapies, targeted agents, and combinations such as rituximab with lenalidomide. The recent approval of epcoritamab added to R² represents an important advancement, providing a novel mechanism of action that enhances the standard backbone. Its integration into this regimen increases clinician confidence by potentially boosting response rates and overcoming resistance, while maintaining a manageable safety profile, ultimately broadening options for this challenging patient population.